Claims for Patent: 5,811,233

Summary for Patent: 5,811,233

Title:	Compositions and uses thereof in the diagnosis of psoriasis
Abstract:	A psoriasis susceptibility locus defined as among linked members within a family has been identified. The locus is linked to an intron of the interleukin enhancer binding factor gene in some families, while being linked to an interleukin 8 gene in other families demonstrating a familial linked form of psoriasis. The locus identified may be further defined as being located distal to genetic maker D17S784 of human chromosome 17q. This locus does not demonstrate linkage with DNA markers within flanking the HLA cluster of genes. A psoriasis susceptibility locus has also been observed close to the centromere of human chromosome 4. Both identified regions provide positive LOD scores with markers on chromosomes 17q and particularly 2 regions close to the ILF gene or the interleukin 8 gene. Methods of screening a family for psoriasis susceptibility using a defined familial psoriasis susceptibility locus are also disclosed. A cDNA capable of detecting a genetic polymorphism identifying the psoriasis susceptibility locus in families with a psoriasis afflicted member, and a process for preparing such a cDNA, are further disclosed. The molecular probes disclosed herein are also known to hybridize with the distal region of human chromosome 17q and with chromosome 4q, and therefore are useful for detecting a genetic lesion in chromosome 17q and 4q. A psoriasis gene related to familial forms of psoriasis is also disclosed. This gene maps to the distal end of human chromosome 17q and has close proximity or is within a gene encoding interleukin enhancer binding factor.
Inventor(s):	Bowcock; Anne (Dallas, TX), Tomfohrde; James (Arlington, TX), Menter; Alan (Dallas, TX), Gaynor; Richard (Dallas, TX)
Assignee:	Board of Regents, Univ. of Texas System (Austin, TX)
Application Number:	08/246,855
Patent Claims:	1. A method for screening for psoriasis susceptibility comprising: (a) obtaining a nucleic acid sample from a patient suspected of having susceptibility to psoriasis; and (b) determining whether a polymorphic marker associated with a familial psoriasis susceptibility locus is present; wherein said polymorphic marker is linked with a gene for interleukin enhancer binding factor. 2. The method of claim 1 wherein the sample is screened with a probe comprising a sequence that hybridizes to a distal region of human chromosome 17q. 3. The method of claim 1, wherein the sample is screened with a probe comprising an intron sequence of human chromosome 17q, said intron sequence further defined as located distal to genetic marker D17S784 of human chromosome, 17q and within a gene encoding for interleukin enhancer binding factor. 4. The method of claim 1, wherein tee sample is screened with a probe comprising the nucleotide sequence as set forth in any one of SEQ ID NOS:4-6, or a sequence complementary to said nucleotide sequence. 5. The method of claim 1, wherein the sample is screened with a nucleic acid molecule comprising the nucleotide sequence as set forth in SEQ ID NO:6, or a fragment of said nucleotide sequence of from 15 to 100 nucleotides. 6. The method of claim 1 wherein the polymorphic marker is distal to genetic marker D17S784 of human chromosome 17q. 7. The method of clam 1 wherein the sample is screened with a probe having a sequence complementary to a region 5' of an intron containing a PstI or PvuII polymorphism within the gene for interleukin enhancer binding factor, or a probe having a sequence complementary to a region 3' to the intron, said probe having a length of between 18 bp and 1 million bp. 8. The method of claim 7 wherein the probe has a length of between 400 bp and 2,000 bp. 9. The method of claim 8 wherein the probe has a length of 450 bp. 10. The method of claim 8 wherein the probe is further defined as comprising the nucleotide sequence as set forth in SEQ ID NO:6, or its complement. 11. The method of claim 7 wherein the probe is further defined as comprising the nucleotide sequence as set forth in SEQ ID NO:4 or SEQ ID NO:5. 12. The method of claim 7 wherein the probe is further defined as comprising a nucleotide sequence that is complementary to the sequence as set forth in SEQ ID NO:4, or complementary to the sequence as set forth in SEQ ID NO:5. 13. The method of claim 1 wherein the polymorphic marker is linked to an intron of the interleukin enhancer binding factor gene. 14. The method of claim 13 wherein the polymorphic marker is further defined as a PvuII polymorphism. 15. The method of claim 13 wherein the polymorphic mark is further defined as a PstI polymorphism. 16. The method of claim 1, wherein the sample is screened with a probe for detecting a polymorphic marker associated with a familial psoriasis susceptibility locus in families with a psoriasis afflicted member, said probe having a DNA sequence mapping within about 11 cM region distal to a genetic marker D17S754 of human chromosome 17q, said probe prepared by a process comprising the steps of: (a) obtaining yeast artificial chromosomes containing human sequences from chromosome 17q between markers D17S784 and D17S928; (b) obtaining a cosmid library containing human sequences from chromosome 17q; (c) selecting cosmids having sequences represented in the yeast artificial chromosome library; (d) obtaining tissue specific primary cDNAs; (e) selecting a cDNA from the primary cDNAs having sequences represented in the selected cosmids; and (f) screening the selected cDNA for sequences that map to human chromosome 17q wherein said DNA of said probe is a sequence that maps and hybridizes to a region distal to genetic marker D17S784 of human chromosome 17q. 17. The method of claim 16 wherein the hybridization of the DNA sequence to a human DNA sequence detects a sequence altered from a wild-type sequence in a sample DNA from a patient with a familial form of psoriasis. 18. The method of claim 16 wherein the step of obtaining yeast artificial chromosomes includes the steps of: (a) annealing sequences of DNA having between 15 to 40 nucleotides from a region of human chromosome 17 distal to genetic marker D17S784 with a human chromosome 17 YAC library; and (b) selecting the human chromosome YACs that bind the sequences. 19. The method of claim 16 wherein the selecting cosmids step includes the steps of: (a) obtaining probes from the yeast artificial chromosomes using inverse repeated sequence polymerase chain reaction probes; (b) annealing the probes with human DNA having repetitive sequence; (c) incubating the annealed probes with the cosmid library; and (d) selecting cosmids which bind the annealed probes. 20. The method of claim 16 wherein the tissue-specific primary cDNA are obtained from epithelial cells, activated T-cells, or keratinocytes. 21. The method of claim 16 wherein the selecting a cDNA step includes the steps of: (a) adding linkers to the primary cDNAs to form linkered cDNA; (b) amplifying the linkered cDNA; (c) labeling the cosmids to form labeled cosmids; (d) hybridizing labeled cosmids to the linkered cDNA; and (e) isolating linkered cDNA that hybridizes to the labeled cosmids. 22. The method of claim 16 wherein the screening step further comprises hybridizing the selected cDNA to DNA samples from psoriasis affected members in genetically linked psoriasis families. 23. The method of claim 16 wherein the screening step further comprises sequencing the selected cDNA and corresponding DNA from affected members in psoriasis linked-families. 24. A method for detecting a genetic polymorphism associated with familial psoriasis in a chromosome 17q distal region comprising: (a) identifying a patient suspected of having a susceptibility for developing psoriasis; (b) preparing a probe that includes a sequence that hybridizes to a polymorphic region at the distal end of human chromosome 17q; (c) contacting a DNA sample isolated from a human tissue of the patient with the probe for a sufficient amount of time to allow for the specific hybridization of the sample DNA to the probe under stringent hybridization conditions; and (d) determining the presence of specific hybridization between the sample DNA and the probe; wherein the presence of specific hybridization of the probe and the sample DNA provides for the detection of a genetic polymorphism associated with familial psoriasis susceptibility at the distal end of human chromosome 17q. 25. The method of claim 24, wherein the probe hybridizes with a polymorphic marker linked with a gene for interleukin enhancer binding factor. 26. The method of claim 25, wherein the probe hybridizes with a polymorphic marker defined by an intron of the gene for interleukin enhancer binding factor. 27. A DNA probe comprising a polymorphism located within an intron region of the gene encoding for interleukin enhancer binding factor, said intron region being located within a region of the interleukin binding factor gene sequence flanked by the nucleic acid sequences as set forth in SEQ ID NO:4 and SEQ ID NO:5. 28. A method for identifying a nucleic acid sequence for screening for familial psoriasis susceptibility comprising: (a) obtaining a nucleic acid sample from a patient having psoriasis or suspected of having susceptibility to psoriasis; (b) identifying a family specific allele comprising a polymorphic marker associated with a familial psoriasis susceptibility locus, wherein the polymorphic marker is present in the patient's nucleic acid sample and is not present in a control nucleic acid sample, and wherein the polymorphic marker maps to chromosome 4 between 4q13 and 4q21; and (c) identifying a nucleic acid sequence that can be used to detect the polymorphic marker; thereby identifying a nucleic acid sequence for screening for familial psoriasis susceptibility. 29. The method of claim 28 wherein the polymorphic marker has a recombination factor with genetic marker D4S400 of about 0.036 and an lod score of about 4. 30. The method of claim 28 wherein the polymorphic marker is linked with a gene for interleukin 8. 31. The method of claim 28, wherein the nucleic acid sequence comprises the nucleotide sequence as set fort in any one of SEQ ID NOS:7-16. 32. An isolated DNA segment of from 20 to 100 nucleotides in length and comprising the nucleic acid sequence as set forth in any one of SEQ ID NOS:7-16, or a sequence complementary to said nucleic acid sequence.

Details for Patent 5,811,233

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26